Altimmune Inc
ALT3.615USD
+0.005+0.14%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
281.34MCap. mercado
PérdidaP/E TTM
Más Datos de Altimmune Inc Compañía
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Información de la empresa
Símbolo de cotizaciónALT
Nombre de la empresaAltimmune Inc
Fecha de salida a bolsaOct 06, 2005
Director ejecutivoDr. Vipin K. Garg, Ph.D.
Número de empleados59
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 06
Dirección910 Clopper Road
CiudadGAITHERSBURG
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal20878-1361
Teléfono12406541450
Sitio Webhttps://altimmune.com/
Símbolo de cotizaciónALT
Fecha de salida a bolsaOct 06, 2005
Director ejecutivoDr. Vipin K. Garg, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
+5.96%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
34.90K
+138.08%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
2.77K
--
Dr. Catherine Angell (Cathy) Sohn, Pharm.D.
Dr. Catherine Angell (Cathy) Sohn, Pharm.D.
Independent Director
Independent Director
1.00K
--
Mr. Philip L. Hodges
Mr. Philip L. Hodges
Independent Director
Independent Director
--
--
Mr. Jerome Benedict (Jerry) Durso
Mr. Jerome Benedict (Jerry) Durso
Director
Director
--
--
Dr. M. Scot Roberts, Ph.D.
Dr. M. Scot Roberts, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Vipin K. Garg, Ph.D.
Dr. Vipin K. Garg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
355.08K
+5.96%
Mr. Raymond M. (Ray) Jordt
Mr. Raymond M. (Ray) Jordt
Chief Business Officer
Chief Business Officer
34.90K
+138.08%
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Dr. Mitchel B. (Mitch) Sayare, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
26.36K
--
Mr. Gregory L. (Greg) Weaver
Mr. Gregory L. (Greg) Weaver
Chief Financial Officer
Chief Financial Officer
10.00K
--
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Brig. Gen. (Retd.) Klaus O. Schafer, M.D.
Independent Director
Independent Director
9.18K
--
Mr. John M. Gill
Mr. John M. Gill
Independent Director
Independent Director
2.77K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 29 de jul
Actualizado: mar., 29 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
6.82%
The Vanguard Group, Inc.
5.42%
State Street Global Advisors (US)
4.18%
Tang Capital Management, LLC
3.39%
Geode Capital Management, L.L.C.
2.10%
Other
78.09%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
6.82%
The Vanguard Group, Inc.
5.42%
State Street Global Advisors (US)
4.18%
Tang Capital Management, LLC
3.39%
Geode Capital Management, L.L.C.
2.10%
Other
78.09%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
21.43%
Investment Advisor/Hedge Fund
14.99%
Hedge Fund
8.48%
Research Firm
2.10%
Individual Investor
0.76%
Bank and Trust
0.36%
Pension Fund
0.23%
Insurance Company
0.04%
Other
51.61%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
412
39.48M
48.67%
-13.27M
2025Q1
433
39.51M
48.72%
-15.43M
2024Q4
439
41.91M
54.50%
-15.25M
2024Q3
440
40.83M
57.43%
-21.59M
2024Q2
436
43.67M
61.47%
-20.29M
2024Q1
418
45.76M
64.68%
-11.45M
2023Q4
387
34.44M
49.06%
-14.90M
2023Q3
368
31.34M
59.36%
-25.59M
2023Q2
362
36.16M
68.78%
-25.80M
2023Q1
371
44.34M
90.01%
-16.05M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
5.53M
6.82%
-133.00K
-2.35%
Mar 31, 2025
The Vanguard Group, Inc.
4.39M
5.42%
-24.15K
-0.55%
Mar 31, 2025
State Street Global Advisors (US)
3.39M
4.18%
-78.45K
-2.26%
Mar 31, 2025
Tang Capital Management, LLC
2.75M
3.39%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.71M
2.1%
+47.38K
+2.86%
Mar 31, 2025
Two Sigma Investments, LP
1.41M
1.74%
+741.11K
+110.45%
Mar 31, 2025
Columbia Threadneedle Investments (UK)
1.32M
1.63%
-3.78M
-74.03%
Mar 31, 2025
Marshall Wace LLP
1.17M
1.44%
+1.10M
+1683.26%
Mar 31, 2025
Knoll Capital Management, LLC
1.12M
1.38%
--
--
Mar 31, 2025
Millennium Management LLC
1.11M
1.37%
+765.66K
+221.52%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Roundhill GLP-1 & Weight Loss ETF
2.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.49%
Invesco NASDAQ Future Gen 200 ETF
0.32%
Federated Hermes MDT Small Cap Core ETF
0.27%
Amplify Weight Loss Drug & Treatment ETF
0.22%
SPDR S&P Biotech ETF
0.1%
Fidelity Enhanced Small Cap ETF
0.07%
iShares Micro-Cap ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
Invesco Nasdaq Biotechnology ETF
0.03%
Ver más
Roundhill GLP-1 & Weight Loss ETF
Proporción2.06%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.49%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.32%
Federated Hermes MDT Small Cap Core ETF
Proporción0.27%
Amplify Weight Loss Drug & Treatment ETF
Proporción0.22%
SPDR S&P Biotech ETF
Proporción0.1%
Fidelity Enhanced Small Cap ETF
Proporción0.07%
iShares Micro-Cap ETF
Proporción0.07%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.06%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
